Skip to main content
Premium Trial:

Request an Annual Quote

ExonHit to Participate in European Alzheimer's Research Effort

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – RNA-based diagnostics and drug developer ExonHit Therapeutics will provide transcriptomics analysis services and its SpliceArray to a European public and private-funded consortium that is focused on identifying new biomarkers for Alzheimer's disease, the Paris-based company said today.

The company said that it will provide its SpliceArray technology and related services to the European Innovative Medicines Initiative (IMI) consortium's PharmaCog effort, which is focused on developing new translational tools, and ultimately a new drug candidate for Alzheimer's treatment.

"ExonHit's unique understanding of transcriptomics analysis will be critical to PharmaCog as it could enable the identification of blood-based markers of disease presence and progression," Olivier Blin, who heads the Center of Clinical Pharmacology and Therapeutic Evaluations at Marseilles Hospital, in a statement. "Such markers are critical in drug development because they provide scientists with greater insights on how results found during preclinical testing are more likely to be reproduced in the clinic."

ExonHit offer the AclarusDx Alzheimer's test for stratifying patients, and it also has developed a Phase 2 drug compound for Alzheimer's disease.

IMI has a total budget of €2 billion ($2.7 billion), and PharmaCog has a budget of €20 million, with €9 million coming from IMI and €11 million from the European Federation of Pharmaceutical Industries and Associations.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.